A new trading day began on Friday, with Denali Therapeutics Inc (NASDAQ: DNLI) stock price down -3.61% from the previous day of trading, before settling in for the closing price of $16.60. DNLI’s price has ranged from $15.45 to $33.31 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 264.19%. Meanwhile, its annual earnings per share averaged -144.22%. With a float of $112.29 million, this company’s outstanding shares have now reached $138.39 million.
Considering the fact that the conglomerate employs 445 people, you should pay attention to its efficiency factor.
Denali Therapeutics Inc (DNLI) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Denali Therapeutics Inc is 19.31%, while institutional ownership is 78.45%. The most recent insider transaction that took place on Apr 15 ’24, was worth 30,471. In this transaction Director of this company sold 1,666 shares at a rate of $18.29, taking the stock ownership to the 118,043 shares. Before that another transaction happened on Apr 01 ’24, when Company’s Director sold 92,500 for $20.50, making the entire transaction worth $1,896,250. This insider now owns 47,341 shares in total.
Denali Therapeutics Inc (DNLI) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of 16.00 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -144.22% per share during the next fiscal year.
Denali Therapeutics Inc (NASDAQ: DNLI) Trading Performance Indicators
Here are Denali Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 13.65. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.74.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.09, a number that is poised to hit -0.70 in the next quarter and is forecasted to reach -2.53 in one year’s time.
Technical Analysis of Denali Therapeutics Inc (DNLI)
Compared to the last year’s volume of 1.16 million, its volume of 1.22 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 1.70%. Additionally, its Average True Range was 0.92.
During the past 100 days, Denali Therapeutics Inc’s (DNLI) raw stochastic average was set at 6.13%, which indicates a significant increase from 2.03% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 43.56% in the past 14 days, which was lower than the 78.30% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $19.17, while its 200-day Moving Average is $21.05. Nevertheless, the first resistance level for the watch stands at $16.56 in the near term. At $17.12, the stock is likely to face the second major resistance level. The third major resistance level sits at $17.45. If the price goes on to break the first support level at $15.68, it is likely to go to the next support level at $15.35. Should the price break the second support level, the third support level stands at $14.79.
Denali Therapeutics Inc (NASDAQ: DNLI) Key Stats
With a market capitalization of 2.23 billion, the company has a total of 139,160K Shares Outstanding. Currently, annual sales are 330,530 K while annual income is -145,220 K. The company’s previous quarter sales were 1,270 K while its latest quarter income was -99,350 K.
